RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at biomarker expression in bone marrow samples from patients with acute myeloid leukemia.
OBJECTIVES: * Estimate the distributions of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms (SNPs) in patients with newly diagnosed acute myeloid leukemia (AML). * Estimate the distributions of mutations in TOP2 phosphorylation sites (by SNP analysis) in these patients. * Investigate whether expression of TOP2 or mutations in TOP2 phosphorylation sites vary with patient or disease characteristics in these patients. * Test whether TOP2 expression correlates with complete remission rates, relapse-free survival, and overall survival of these patients. * Conduct preliminary analyses to estimate the distributions of TOP2 expression and mutations in TOP2 phosphorylation sites (by SNP analysis) in patients with relapsed and/or refractory AML. * Investigate whether expression of TOP2 and mutations in TOP2 phosphorylation sites vary with patient or disease characteristics in patients with relapsed and/or refractory AML. * Test whether TOP2 expression and mutations in TOP2 phosphorylation sites differ between previously untreated and relapsed/refractory AML patients. OUTLINE: This is a multicenter study. Archived RNA specimens are analyzed for topoisomerase 2 transcriptional expression by quantitative real-time polymerase chain reaction (PCR) and for mutations within TOP2 phosphorylation sites by single nucleotide polymorphism analysis.
Study Type
OBSERVATIONAL
Enrollment
357
Distribution of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms
Time frame: immediate
Distributions of mutations in TOP2 phosphorylation sites
Time frame: immediate
Correlation of TOP2 expression with complete remission rates, relapse-free survival, and overall survival
Time frame: immediate
Variation of TOP2 expression and mutations in TOP2 phosphorylation sites among patients and disease characteristics
Time frame: immediate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.